Browse by regulation1 article · 1 high
WHO-PQ GMP Guidelines / ICH Q10
Every DSRV article whose Regulatory Snapshot cites WHO-PQ GMP Guidelines / ICH Q10: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
Inspection exposure across the set
- What has FDA cited under WHO-PQ GMP Guidelines / ICH Q10?
- 1 DSRV article cite WHO-PQ GMP Guidelines / ICH Q10. Enforcement cases behind them: NAFDAC 5+5 Policy results published March 2026: 191 applications, 185 approved, 108 facility layouts cleared, 20 completed, 88 under construction. 58% first-time manufacturers. Inspection exposure across them: 1 high.
- What does DSRV recommend for WHO-PQ GMP Guidelines / ICH Q10?
- From the newest article (108 New Drug Facilities in Nigeria. Most Have Never Been Inspected.): NAFDAC approval confirms a facility was built. It does not confirm the quality system inside it is ready for WHO-PQ or FDA scrutiny. The 63 first-time manufacturers entering Nigeria's supply chain carry inspection risk proportional to their lack of prior GMP testing. DSRV is decision support, not legal advice; verify against the official source each article names.
In brief
Address this risk
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under WHO-PQ GMP Guidelines / ICH Q10. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.